Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ABBOTT INDIA LTD.

NSE : ABBOTINDIABSE : 500488ISIN CODE : INE358A01014Industry : Pharmaceuticals & DrugsHouse : Abbott India - MNC

BSE26055.65-35.7 (-0.14 %)

PREV CLOSE ( ) 26091.35

OPEN PRICE ( ) 26296.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 292

TODAY'S LOW / HIGH ( )25982.00 26421.95

52 WK LOW / HIGH ( )20594.25 29628.15

NSE26065.20-79.55 (-0.3 %)

PREV CLOSE( ) 26144.75

OPEN PRICE ( ) 26224.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 9484

TODAY'S LOW / HIGH( ) 25986.00 26416.70

52 WK LOW / HIGH ( )20605.05 29638.95

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 22-08 1944

Management Info

Munir Shaikh - Chairman - Managing Director

Registered Office

Address Unit No. 3,Corporate Park,Sion Trombay Road,
Mumbai,
Maharashtra-400071

Phone 022-50461000 / 2000 / 67978888

Email webmasterindia@abbott.com / investorrelations.india@abbott.com

Website www.abbott.co.in

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

12Apr Abbott India informs about appointment
In compliance with Regulation 30 of the Securities and Exchange Board of..

27Mar Abbott India informs about newspaper a
Pursuant to Regulation 47 of the Securities and Exchange Board of India..

19Mar Abbott India informs about resignation
With reference to its earlier communication dated December 19, 2023, whe..

15Mar Abbott India informs about change in s
Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Sche..

13Mar Abbott India informs about change in d
Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Sche..

Financials

Rs. in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	3109.8	9494.1
Gross Profit	4221.6	12738.2
Operating Profit	4433	13597.8
Net Sales	14371.4	53487.3

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE) 2542.60 (12.29%)	M.Cap ( in Cr)1570.82
Neuland Laboratories (BSE) 7654.80 (1.79%)	M.Cap ( in Cr)9821.02
Mankind Pharma (BSE) 2397.40 (5.05%)	M.Cap ( in Cr)96037.07
Sanofi India (BSE) 8470.70 (0.89%)	M.Cap ( in Cr)19508.55
Solara Active Pharma (BSE) 474.10 (12.15%)	M.Cap ( in Cr)1706.58

Shareholding Pattern

	PROMOTERS	74.99%
	NON-INSTITUTION	15.92%
	MUTUAL FUNDS/UTI	7.57%
	FI/BANKS/INSURANCE	1.23%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
SBI Magnum Global F...	5.75
LIC MF Healthcare F...	4.51
NJ ELSS Tax Saver S...	3.76
SBI Healthcare Opp ...	3.72
Nippon India Pharma...	3.29
Aditya Birla SL Pha...	3.10
Samco ELSS Tax Save...	3.10

Risk Disclosures on Derivatives

Smart Quotes

ABBOTT INDIA LTD.